Published in final edited form as:

J Community Support Oncol. 2015 May ; 13(5): 188–194.

Symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment

Mary Lou Siefert, DNSc, RN, AOCN^a, Traci M Blonquist, MS^b, Donna L Berry, PhD, RN, FAAN^{a,c}, and Fangxin Hong, PhD^b

^aPhyllis F. Cantor Center, Dana-Farber Cancer Institute, Boston, Massachusetts

^bBiostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

^cDepartment of Medicine, Harvard Medical School, Boston, Massachusetts

Abstract

Background—People with cancer experience symptoms related to the disease and treatments. Symptom distress has a negative impact on quality of life (QoL). Attending to symptoms and side effects of treatment promotes safe and effective delivery of therapies and may prevent or reduce emergency department visits (EDVs) and unplanned hospital admissions (HAs). There is limited evidence examining symptom-related EDVs or HAs (sx-EDV/HAs) and interventions in ambulatory oncology patients.

Objective—To examine factors associated with sx-EDV/HAs in ambulatory oncology patients receiving chemotherapy and/or radiation.

Methods—This secondary analysis used data from a randomized controlled trial of ambulatory oncology patients (n = 663) who received the web-based Electronic Self-Report Assessment - Cancer intervention (symptom self-monitoring, tailored education, and communication coaching) or usual care with symptom self-monitoring alone. Group differences were described by summary statistics and compared by *t* test. Factors associated with the odds of at least 1 sx-EDV/HA were modeled using logistic regression.

Results—98 patients had a total of 171 sx-EDV/HAs with no difference between groups. Higher odds of at least 1 sx-EDV/HA were associated with socioeconomic and clinical factors. The multivariable model indicated that work status, education level, treatment modality, and on-treatment Symptom Distress Scale-15 scores were significantly associated with having at least 1 sx-EDV/HA.

Limitations—This is a secondary analysis not sized to determine cause and effect. The results have limited generalizability.

Conclusion—Most patients did not experience an sx-EDV/HA. Demographic and clinical factors predicted an sx-EDV/HA.

Correspondence: Mary Lou Siefert, DNSc, RN, AOCN; maryl_siefert@dfci.harvard.edu.

Disclosures: The authors have no disclosures.

ClinicalTrials.gov identifier: NCT00852852.

Funding—National Institute of Nursing Research, National Institutes of Health, R01 NR008726; 2008–2011

People with cancer can experience distress associated with symptoms stemming from the disease itself and/or symptoms resulting from treatments and associated side effects. Symptom distress has a negative impact on patient quality of life (QoL), affecting the physical, psychological, social, and spiritual domains of life.¹ Managing cancer symptoms and QoL issues are high priorities for oncology clinicians.² Furthermore, attending to symptoms and side effects of treatment promotes safe and effective delivery of cancer therapies and may prevent or reduce the use of emergency department (ED) services and unplanned hospital admissions (HAs).

The results of several descriptive, retrospective studies examining the clinical factors associated with emergency department visits (EDVs) and hospital admissions (HAs) in people with cancer suggest that relevant factors include symptoms and diagnoses.^{3–5} Common symptoms associated with EDVs and HAs in people with cancer include pain, gastrointestinal symptoms, fever, dyspnea, and nausea and vomiting.^{3,5–7} Patients who have had a recent hospitalization are at increased risk of another HA.⁴ In addition, people with lung cancer^{3,5,6} and those with respiratory and other comorbid conditions may also be at increased risk of an EDV or HA.^{4,8}

In summary, symptoms, cancer diagnoses, and comorbid conditions are associated with EDVs and HAs. Fever alone or fever with neutropenia is a strong predictor of an EDV or HA in people receiving chemotherapy or with newly diagnosed cancers, including hematologic malignancies.^{6,7} Other symptoms including pain, problems related to the gastrointestinal and respiratory systems, and specific cancer diagnoses are also associated with EDVs and HAs. Attending to symptoms and problems before presentation to the ED may prevent or reduce use of ED services and the number of HAs.

We found 4 studies that examined cancer symptom management and EDVs and HAs in: women with gynecologic cancer,⁹ ambulatory patients with breast or lung cancer receiving chemotherapy or radiation therapy,¹⁰ patients with head and neck cancer receiving concurrent chemo-radiotherapy,¹¹ and a sample of patients receiving chemotherapy for the first time.⁸ EDV and HA outcomes reported in those studies were mixed, suggesting that further investigation is needed.

Most studies that have focused on EDVs and HAs in people with cancer were retrospective and medical record reviews; intervention studies have been mostly limited to patients receiving chemotherapy only. Therefore, we planned an analysis of prospective trial data from patients with various diagnoses and therapies. The purpose of this study was to examine the factors associated with symptom-related EDV/HAs (sx-EDV/HAs) in ambulatory oncology patients who were receiving chemotherapy and/or radiation therapy.

Methods

Study design and sample

This secondary analysis used data from a randomized controlled trial of the Electronic Self-Report Assessment for Cancer (ESRA-C).¹² The trial was conducted in 2 comprehensive cancer centers during April 2009-June 2011 with approval by the Institutional Review Boards of the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium and the Dana-Farber/Harvard Cancer Center. A total of 752 eligible adult, ambulatory patients with any type of cancer, who had started a new therapeutic regimen, were enrolled and randomized. The web-based ESRA-C intervention is an easy-to-use, patient-centered technology with patient-self-report assessments plus education tailored to moderate and severe symptom and quality of life reports, and provides patient-to-provider communication coaching. Participants in both trial groups used ESRA-C to self-report symptoms and quality of life (sx-QoL) once at each of the following study time points: T1, before starting a new cancer therapy; T2, at 3–6 weeks; T3, 6–8 weeks after T2; and T4, at the end of the therapy regimen. Randomized trial outcomes resulted in significantly lower symptom distress over the course of treatment and significantly more frequent detailed patient communication of sx-QoL.^{12,13}

Most of the sx-EDV/HAs (58%) occurred within the first 2 months on study, therefore only the sx-QoL reports at T1 (baseline) and T2 (first on-treatment time point) were used for this analysis. Treatment and EDV/HA data from a medical record review were available for 663 participants (327 control, 336 intervention) who received chemotherapy and/or radiation therapy. A sx-EDV/HA was defined as an EDV or HA that was initiated with a patient-reported symptom. All reported EDVs and HAs were documented as mutually exclusive events; an EDV that resulted in an HA was coded as an HA.

Analysis

The number of sx-EDV/HAs were described with summary statistics and compared between the study groups with a 2-group, unequal variance *t* test. A *t* test was deemed appropriate given the large sample size of the study.¹⁴ In addition, the odds of having at least 1 sx-EDV/HA were modeled using logistic regression considering a list of pre-selected variables including study group, financial difficulties, work status, education level, minority status, gender, age, stage, emotional functioning, Symptom Distress Scale-15 score (SDS-15), depression, months on study, age-adjusted comorbidity, and treatment type (radiation, chemotherapy, or both). Sociodemographic characteristics were collected at baseline only. Covariates were first assessed with univariate analyses and then adjusted in a multivariable analysis. The backwards elimination method was used with the Akaike information criterion (AIC) for variable selection in the multivariable model. Type III *P* values were used to assess the overall significance and variables with a *P* value of .1 or less were retained in the model. All analyses were conducted in SAS (version 9.2) and R (version 2.15.2).

Results

Baseline sociodemographic, clinical, and environmental characteristics for the total sample ($N = 663$; 327 control and 336 intervention) are provided in Table 1. Of the total number of patients, 49 of the 327 control patients had at least 1 sx-EDV/HA, accounting for 96 total sx-EDV/HAs. Of the 336 intervention patients, 49 had at least 1 sx-EDV/HA, for a total of 75 sx-EDV/HAs. The most common reasons for an sx-EDV/HA were pain, fever, and nausea. Forty-seven patients presented with pain for a total of 74 EDV/HAs, 37 presented with a fever for a total of 52 EDV/HAs, and 23 presented with nausea for a total of 40 EDV/HAs (Table 2). A majority of the patients (85%) did not have any sx-EDV/HAs during the analytic period. Of the patients with at least 1 sx-EDV/HA, 58% had only 1, 28% had 2, 7% had 3, 4% had 4, and 3% had 5 or more (data not shown). On average, each patient had 0.26 sx-EDV/HA overall, which corresponds to about 1 sx-EDV/HA in 4 patients. There was no statistically significant group difference in the mean number of sx-EDV/HAs ($P = .28$); 0.22 sx-EDV/HA per patient (roughly 1 in 5) in the intervention group, and 0.29 sx-EDV/HA per patient (roughly 1 in 4) in the control group.

The results from univariate analyses (Figure 1) suggest that higher odds of at least 1 sx-EDV/HA were associated with not working ($P = .001$, OR = 2.13, 90% CI, 1.46–3.13), lower education ($P = .008$, OR = 1.92, 90% CI, 1.29–2.90), stage IV disease ($P < .0001$, OR = 2.40, 90% CI, 1.67–3.46), receiving chemotherapy alone compared with radiation alone ($P = .003$, OR = 5.25, 90% CI, 2.56–10.79), and receiving chemotherapy and radiation compared with radiation alone ($P = .004$, OR = 5.61, 90% CI, 2.59–12.16). Higher odds of an sx-EDV/HA also were associated with a higher SDS-15 score at T1 ($P < .0001$) and a higher SDS-15 score at T2 ($P < .0001$), with an odds ratio of 1.83 (90% CI, 1.45–2.33) at T1 and 1.83 (90% CI, 1.43–2.34) at T2 per 10-point increase on SDS-15. In addition, higher odds of an sx-EDV/HA were associated with higher depression at T1 ($P = .02$, OR = 1.8, 90% CI, 1.20–2.71) and T2 ($P = .0002$, OR = 2.64, 90% CI, 1.71–4.07), and longer time on study ($P = .02$, OR = 1.52, 90% CI, 1.13–2.04). Comparatively, a 10-point decrease in emotional functioning was associated with higher odds of an sx-EDV/HA at T1 ($P = .003$, OR = 1.16, 90% CI, 1.08–1.27) and T2 ($P = .001$, OR = 1.19, 90% CI, 1.08–1.30). The odds of at least one sx-EDV/HA was not significantly different by gender ($P = .41$).

Emotional functioning, depression, and SDS-15 scores, at both T1 and T2, were highly correlated (data not shown). Working status and stage of disease also were strongly associated ($P < .0001$). Each of the correlated sxQoL scores were modeled separately and the backwards elimination method yielded three possible models involving T1 SDS-15, T2 SDS-15, and T2 depression. The common significant variables in each of the models were education and treatment modality. By the AIC criterion, the selected multivariable model indicated that work status ($P = .0003$), education level ($P = .008$), treatment modality ($P = .03$), and the T2 SDS-15 score ($P = .0003$) were significantly predictive of having at least 1 sx-EDV/HA. Similar to that in the univariate analyses, the higher odds of at least 1 sx-EDV/HA were associated with not working (OR = 2.22, 90% CI, 1.39–3.57), lower education (OR = 2.33, 90% CI, 1.37–3.85), chemotherapy versus radiation (OR = 5.27, 90% CI, 1.90–14.59), chemotherapy and radiation versus radiation (OR = 5.82, 90% CI, 2.00–16.88), and an increase in T2 SDS-15 (OR = 1.07, 90% CI, 1.04–1.10). When adjusting for

other factors, the study group was not significantly associated with the odds of at least 1 sx-EDV/HA (Table 3).

Discussion

In a sample of ambulatory oncology patients with various cancer diagnoses, we found that pertinent sociodemographic and clinical factors were associated with sx-EDV/Has, which included education level, work status, symptom distress, and treatment with chemotherapy with or without radiation compared with radiation alone. Our participants had a lower rate of sx-EDV/HAs than the rates reported in retrospective medical record review studies examining factors associated with the frequencies of EDVs and HAs.^{6,7,15}

In other studies of ambulatory oncology patients who were receiving chemotherapy, frequencies varied widely for any type of EDV or HA.^{6,7} Livingston and colleagues⁶ reported 772 of 2,380 oncology outpatients (32.5%) used the ED at least once, with a range of 1–15 visits per patient; more than half of the EDVs required an HA. In McKenzie and colleagues,⁷ 233 of 316 (73.7%) patients who had received chemotherapy within six months made an EDV and 87.6% of all EDVs resulted in an HA. Our data were from patients who had enrolled in a clinical trial and may have been more conscious of care and symptom management at home. All of the patients were receiving active treatment and reporting symptoms regularly; all of the providers were given patient report summaries before each outpatient visit. The self-reporting in the intervention group and provider reports may have increased early recognition, awareness, and treatment of symptoms before they escalated to problems that would warrant an EDV or HA. Also, we limited our analysis to sx-EDV/HAs, whereas other studies reported all EDVs or HAs, including, for example, comorbidities and cancer diagnoses; the visits or admissions were not reported separately by associated factors.

Not surprisingly, we found that greater symptom distress while on treatment was associated with the higher odds of an sx-EDV/HA. The 3 common presenting symptoms, pain, fever and nausea, in our data, are similar to several retrospective reviews addressing common symptoms or diagnoses^{3–5} associated with EDVs or HAs. Barbera and colleagues³ conducted a large, retrospective review of administrative health care data in Ontario from patients with cancer who had died between 2002–2005 (N = 76,759) and reported that patients made 194,017 EDVs during the last 6 months of life. Abdominal pain was the most common symptom recorded for the sx-EDVs. Other common symptoms associated with sx-EDVs included dyspnea, malaise and fatigue, chest pain, and nausea and vomiting.³ Swenson, and colleagues⁵ also reported gastrointestinal symptoms and pain as the 2 most common symptoms in people with cancer who made an EDV.

In a sub analysis using a randomly selected sample (n = 443) from a retrospective medical record review (N = 2,380) of 2007 data, Livingston and colleagues⁶ reported that fever and neutropenia were the most frequent EDV diagnoses followed by nausea and vomiting, dehydration and abdominal pain for ambulatory patients with cancer. In a sample of patients (N = 363) receiving outpatient chemotherapy, McKenzie and colleagues⁷ reported that fever or fever and neutropenia, and pain were the most common reasons for unplanned hospital presentations.

Our original randomized trial was not planned to detect a significant difference in the rate of sx-EDV/HAs; we observed a lower, though statistically insignificant, rate for the ESRA-C intervention group compared with the control group. In studies examining in-person and telephone nursing interventions that targeted symptoms in people receiving chemotherapy with or without radiation therapy for cancer, differences in rates of EDVs and HAs have been reported for those receiving the intervention compared with those who did not.^{8,9,11} Kurz and colleagues⁸ used a cognitive behavioral nursing intervention over a 20-week period in a sample in which the majority of patients (65%) had late stage disease; symptom severity and the number of comorbidities were predictive of EDVs. The frequency of EDVs was lower in the intervention group, there was a trend toward fewer HAs, and when only those patients with greater symptom severity were examined, there was a reduction in the number of HAs in the intervention group.⁸ McCorkle and colleagues⁹ tested an advance practice nurse (APN) intervention in women with ovarian cancer and found that the intervention group reported more EDVs and there was no difference in HAs between the 2 groups. The authors suggested that the APN may have instructed the women in the intervention group to make an after-hours EDV for evaluation before symptom escalation.⁹ In a retrospective medical record review comparing HAs, in patients who received concurrent chemo-radiotherapy before and after a nurse practitioner-led clinic was established, the patients who were seen regularly in the NP-led clinic experienced fewer HAs.¹¹

In our sample, we found that late-stage disease, highly correlated with not working, was a predictor of sx-EDV/HAs. However, we did not have a sufficient number of patients to analyze the subset of late-stage patients who were likely to have greater symptom severity compared with all other patients for an intervention effect on sx-EDV/HAs.

Some sx-EDV/HAs may be avoidable. It is necessary to first understand the reasons for sx-EDV/HAs to develop interventions to prevent sx-EDV/HAs related to treatable symptoms and to assess patients for those symptoms that may herald a preventable or potentially more serious problem if they are not addressed early. For example, constipation, a common symptom that ranked 11th out of 30 of the most common reasons for an EDV in 1 report,³ can often be prevented when the underlying cause is addressed. Constipation is related to opioid use for pain control in people with cancer and can be prevented when properly managed with laxatives.¹⁶ And, if constipation is the result of other more serious etiologies such as gastrointestinal obstructions, early assessment of the symptom and interventions may prevent sx-EDV/HAs.

Clinicians would be best advised to consider providing greater attention and targeting interventions proactively to those individuals most at risk of an sx-EDV/HA. Our findings indicated that ambulatory oncology patients who have less education, are not working, report greater symptom distress, and are receiving chemotherapy with or without radiation therapy, were more likely to have an sx-EDV/HA. It is not entirely clear why those who were not working were at higher odds of having an sx-EDV/HA; however, work status and disease stage were related. Therefore, it is likely that patients with late-stage cancers were not working, were more burdened by symptoms, and were experiencing worse overall functionality than were those who reported that they were still working.¹⁷ We also found

that patients who were receiving chemotherapy or combined chemotherapy and radiation therapy were at higher odds of an sx-EDV/HA than were those who were receiving radiation therapy alone. In a recently published descriptive study of ambulatory oncology patients who were receiving combined chemotherapy and radiation therapy for head and neck cancer, 13 of the 40 patients (33%) required an unplanned hospitalization during treatment; slightly greater than 50% of HAs (7 of 13) were symptom related.¹⁸

The patients in our study who were receiving radiation therapy alone had lower odds of an sx-EDV/HA. In people who are receiving radiation therapy alone without chemotherapy, the symptoms related to the radiation therapy may be delayed. For example, the severity, frequency,^{19–21} and distress²⁰ associated with fatigue gradually increases during radiation therapy, peaks after therapy is completed, and decreases over several months after therapy. Therefore, the symptom distress in patients receiving radiation therapy alone may not have peaked until after our study period.

Limitations

Our findings cannot be generalized beyond a sample of ambulatory oncology patients who were majority race and ethnicity and college-educated. The original trial sample size was not planned to test differences in sx-EDV/HAs between study groups. All the patients in this sample were ambulatory oncology patients with solid tumors who were receiving active treatment. Furthermore, they were all enrolled in a clinical trial and may have been monitored more closely than the general ambulatory oncology population, possibly resulting in better outcomes than in those who would not be enrolled in a clinical trial²² and/or as a result of the Hawthorne effect.²³ The low number of sx-EDV/HAs limited our ability to study the relationships between EDVs and HAs. In addition, although the symptom-related reason for each EDV/HA was known, the symptom severity was not collected at the time of the sx-EDV/HA. We had no knowledge of other variables that occurred before the study time period.

Future work

There are few intervention studies examining sx-EDV/HAs among ambulatory oncology patients. Future work to confirm that certain groups of individuals, such as ambulatory oncology patients who have greater symptom severity, comorbid conditions, pertinent cancer diagnoses, or those patients who are receiving chemotherapy or who are not working are more likely to have an sx-EDV/HA would be useful information to help plan targeted interventions. Prospective studies that are designed to examine the effects of symptom management interventions and associated use of health care services would be beneficial to assess the impact of interventions and to further identify those who would receive the most benefit.

Conclusions

Overall, most of the patients in this sample of ambulatory oncology patients did not experience a sx-EDV/HA. The predictors associated with having at least 1 sx-EDV/HA were

receiving chemotherapy with or without radiation therapy, lower education level, not working, and higher symptom distress scores. The implementation of symptom management strategies for those who are at high risk of sx-EDV/HAs and the evaluation of outcomes related to sx-EDV/HAs is warranted.

References

1. Ferrell B, Smith SL, Cullinane CA, Melancon C. Psychological well being and quality of life in ovarian cancer survivors. *Cancer*. 2003; 98:1061–1071. [PubMed: 12942576]
2. Ropka ME, Guterbock T, Krebs L, et al. Year 2000 Oncology Nursing Society Research Priorities Survey. *Oncol Nurs Forum*. 2002; 29:481–491. [PubMed: 11979281]
3. Barbera L, Taylor C, Dudgeon D. Why do patients with cancer visit the emergency department near the end of life? *CMAJ*. 2010; 182:563–568. [PubMed: 20231340]
4. López-Aguilá S, Contel JC, Farre J, Campuzano JL, Rajmil L. Predictive model for admission and 6-month readmission. *Am J Manag Care*. 2011; 17:e348–e357. [PubMed: 21902442]
5. Swenson KK, Rose MA, Ritz L, Murray CL, Adlis SA. Recognition and evaluation of oncology-related symptoms in the emergency department. *Ann Emerg Med*. 1995; 26:12–17. [PubMed: 7793714]
6. Livingston PM, Craike M, Considine J. Unplanned presentations to emergency departments due to chemotherapy induced complications: Opportunities for improving service delivery. *Australasian Emerg Nurs J*. 2011; 14:62–68.
7. McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. *Support Care Cancer*. 2011; 19:963–969. [PubMed: 20499108]
8. Kurtz ME, Kurtz JC, Given CW, Given B. Effects of a symptom control intervention on utilization of health care services among cancer patients. *Med Sci Monit*. 2006; 12:CR319–CR324. [PubMed: 16810138]
9. McCorkle R, Jeon S, Ercolano E, Schwartz P. Healthcare utilization in women after abdominal surgery for ovarian cancer. *Nurs Res*. 2011; 60:47–57. [PubMed: 21127451]
10. Skrutkowski M, Saucier A, Eades M, et al. Impact of a pivot nurse in oncology on patients with lung or breast cancer: symptom distress, fatigue, quality of life, and use of healthcare resources. *Oncol Nurs Forum*. 2008; 35:948–954. [PubMed: 18980926]
11. Mason H, DeRubeis MB, Foster JC, Taylor JM, Worden FP. Outcomes evaluation of a weekly nurse practitioner-managed symptom management clinic for patients with head and neck cancer treated with chemoradiotherapy. *Oncol Nurs Forum*. 2013; 40:581–586. [PubMed: 24007925]
12. Berry DL, Hong F, Halpenny B, et al. The electronic self-report assessment for cancer and self-care support: results of a multisite randomized trial. *J Clin Oncol*. 2014; 32:199–205. [PubMed: 24344222]
13. Berry DL, Hong F, Halpenny B, et al. The electronic self report assessment and intervention for cancer: promoting patient verbal reporting of symptom and quality of life issues in a randomized controlled trial. *BMC cancer*. 2014; 14:513. [PubMed: 25014995]
14. Fagerland MW. t-tests, non-parametric tests, and large studies—a paradox of statistical practice? *BMC Med Res Methodol*. 2012; 12:78. [PubMed: 22697476]
15. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. *J Nat Cancer Inst*. 2006; 98:1108–1117. [PubMed: 16912263]
16. Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. *Support Care Cancer*. 2004; 12:613–618. [PubMed: 15221581]
17. Mehnert A. Employment and work-related issues in cancer survivors. *Crit Rev Oncol Hematol*. 2011; 77:109–130. [PubMed: 20117019]
18. Daly ME, Lau DH, Farwell DG, Luu Q, Donald PJ, Chen AM. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer. *Am J Otolaryngol*. 2013; 34:631–635. [PubMed: 23954137]

19. Geinitz H, Zimmermann FB, Stoll P, et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. *Int J Radiat Oncol Biol Phys*. 2001; 51:691–698. [PubMed: 11597810]
20. Hofsø K, Rustøen T, Cooper BA, Bjordal K, Miaskowski C. Changes over time in occurrence, severity, and distress of common symptoms during and after radiation therapy for breast cancer. *J Pain Symptom Manage*. 2013; 45:980–1006. [PubMed: 23026547]
21. Lavdaniti M, Patiraki E, Dafni U, Katapodi M, Papathanasoglou E, Sotiropoulou A. Prospective assessment of fatigue and health status in Greek patients with breast cancer undergoing adjuvant radiotherapy. *Oncol Nurs Forum*. 2006; 33:603–610. [PubMed: 16676016]
22. Baker JR, Vandal AC, Yeoh J, Zeng I, Wong S, Ryan SN. Clinical trial participation improves outcome: a matched historical cohort study. *Clin Trials*. 2013; 10:735–743. [PubMed: 24006245]
23. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. *BMC Med Res Methodol*. 2007; 7:30. [PubMed: 17608932]

Figure 1.
Univariate logistic regression to evaluate the odds of at least one sx-EDV/HA for various predictors.

Table 1

Baseline sample description

Patient Characteristic	Total Sample (N=663)
Age, median (range)	58 (19, 88)
n (%)	
Gender	
Male	333 (50)
Female	330 (50)
Stage	
Stage IV	221 (33)
Other	442 (67)
Race/ethnicity	
Minority	61 (9)
Non-minority	553 (80)
Unknown	69 (10)
Treatment Type	
Chemotherapy	370 (56)
Radiation	151 (23)
Both	138 (21)
Unknown	4 (<1)
Work Status	
Working	392 (59)
Not Working	203 (31)
Unknown	68 (10)
Education Level	
Some College	530 (80)
< Some College	131 (20)
Unknown	2 (<1)
Study Group	
Intervention	336 (51)
Control	327 (49)

Table 2

The total number of EDV/HA visits with presenting symptoms and the number of patients with at least 1 EDV/HA with presenting symptom (N=98)

Symptom	No. of EDV/HA Visits ^a	No. of Patients	% of Patients
With 1 EDV/HA^b			
Anxiety	2	2	2
Anorexia	3	3	3
Bowel	15	10	10
Breath	22	15	15
Cough	13	12	12
Delirium	1	1	1
Depression	2	1	1
Fatigue	11	10	10
Fever	52	37	38
Nausea	40	23	23
Neuropathy	0	0	0
Pain	74	47	48
Skin	5	5	5
Weak	8	8	8
Other	28	26	26

^aThe sum of the number of EDV/HA visit overall; a patient could have had an EDV/HA for more than 1 symptom in a visit and more than 1 EDV/HA is possible per patient.

^bThe number with at least 1 EDV/HA for the given symptom; the percentage, out of 98 patients with at least 1 EDV/HA, for the given symptom.

Table 3

Logistic multivariable regression to evaluate the association between various predictors and the odds of a patient experiencing at least 1 sx-EDV/HA (N=466)

Variable	Selected Model			Containing Study Group		
	Odds Ratio Estimate	p-value	90% CI Odds Ratio	Odds Ratio Estimate	p-value	
Intervention vs. Control	–	–	–	1.08	0.7784	
T2 SDS-15 score ^a	1.07	0.0003	(1.04, 1.10)	1.07	0.0003	
Low vs. High Education	2.23	0.0081	(1.37, 3.87)	2.31	0.0080	
Not Working vs. Working	2.30	0.0048	(1.37, 3.56)	2.23	0.0050	
Treatment Type (Chemotherapy vs. Radiation)	5.27	0.0342	(1.90, 14.59)	5.27	0.0339	
Treatment Type (Chemotherapy & Radiation vs. Radiation alone)	5.82	0.0215	(2.00, 16.88)	5.81	0.0218	

^a 466 out of the 663 had a T2 Symptom Distress Scale-15 score